A new approach to treating the most malignant type of brain cancer – glioblastoma – has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months.
FDA makes device conformity testing scheme permanent to streamline assessments
Dive Brief: The Food and Drug Administration has turned its medical device conformity testing scheme into a permanent program after completing a pilot assessment. Officials
September 20, 2023